August 15, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of blood thinner Plavix and force it to recall product already sold. The companies also said they had begun discounting Plavix to stem the loss of market share. A hearing on the motion is set for Friday in the U.S.
July 21, 2006 |
Three U.S. senators launched an effort Thursday to ban a practice that they say could lead to higher drug prices for consumers by undermining competition in the country's $250-billion pharmaceutical market. The lawmakers introduced a bill to limit the marketing of "authorized generics," which are cheaper versions of branded prescription drugs that are licensed or manufactured by the brand owners.
July 13, 2006 |
A U.S. district judge declined to issue a preliminary injunction blocking two companies from exclusively selling their generic versions of Merck & Co.'s Zocor cholesterol drug. Novartis' Sandoz unit had sought a temporary restraining order against generic manufacturers Teva Pharmaceutical Industries Ltd.'s Ivax and Ranbaxy Laboratories Ltd. U.S.
July 1, 2006 |
The first generic versions of Zoloft received federal approval. Israel's Teva Pharmaceutical Industries Ltd. said it would make generic versions of the antidepressant in 25-, 50- and 100-milligram tablets. Roxane Laboratories Inc., based in Columbus, Ohio, would make a liquid concentrate version of the drug, the Food and Drug Administration said. Pfizer Inc.'s patent on Zoloft expires today.
June 23, 2006 |
Aetna Inc. said Thursday that it would buy discounted copies of the cholesterol drug Zocor from Teva Pharmaceutical Industries Ltd. rather than accept an offer from Merck & Co. to sell its branded pill for less than the generic. Aetna patients will pay more out-of-pocket for Merck's Zocor than Teva's generic, Aetna said. Eric Elliott, Aetna's pharmacy manager, said the Hartford, Conn.
May 26, 2006 |
Israel-based Teva Pharmaceutical Industries Ltd. won tentative U.S. regulatory approval to sell copies of Merck & Co.'s Zocor cholesterol drug, and said sales might start in June. Still at issue is the ability of Teva, the world's biggest generic drug maker, to sell the pills exclusively for six months under a U.S. rule designed to promote cheaper generics.
May 20, 2006 |
The nation's largest pharmacy benefits manager announced Friday that it was distributing more generic drugs than brand-name counterparts, a sign that costly brand-name prescription medicines may be losing their grip on the market, leading to lower drug costs for consumers. The trend is significant because even more generic prescription drugs are expected to hit the market in the near future.
April 5, 2006 |
When two competing generic drugs come on the market, the average generic price can drop to half the cost of the comparable brand-name product, according to a U.S. government study released Tuesday. The study by the Food and Drug Administration found that savings weren't as significant when only one generic drug was on the market: the price of the generic drug is typically 6% less than the brand-name competition.
March 7, 2006 |
GlaxoSmithKline lost a bid to prevent sales of generic versions of its $900-million-a-year allergy drug Flonase. Boehringer Ingelheim's generic version could reach the market today after U.S. District Judge Andre Davis in Baltimore refused to block sales while Glaxo pursues a lawsuit against the Food and Drug Administration.
January 4, 2006 |
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.